Abstract
Primary central nervous system lymphoma (PCNSL) is a subtype of non-Hodgkin's lymphoma that involves the brain, spinal cord, or leptomeninges, without evidence of systemic disease. This rare disease accounts for ~ 3% of all primary central nervous system (CNS) tumors. Methotrexate-based regimens are the standard of care for this disease with overall survival rates ranging from 14 to 55 months. Relapse after apparent complete remission can occur. We sought to understand the outcomes of patients who relapsed. This is an IRB-approved investigation of patients treated at our institution between 12/31/2004 and 10/12/2016. We retrospectively identified all cases of PCNSL as part of a database registry and evaluated these cases for demographic information, absence or presence of relapse, location of relapse, treatment regimens, and median relapse-free survival. This analysis identified 44 patients with a pathologically confirmed diagnosis of PCNSL. Mean age at diagnosis was 63.1 years (range 20-86, SD = 13.2 years). Of the 44 patients, 28 patients successfully completed an initial treatment regimen without recurrence or toxicity that required a change in therapy. Relapse occurred in 11 patients with the location of relapse being in th...Continue Reading
References
Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L M DeAngelisU Kher
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·D F NelsonK J Murray
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lauren E AbreyUNKNOWN International Primary CNS Lymphoma Collaborative Group
May 16, 2006·Journal of Neuro-oncology·Kristoph JahnkeUNKNOWN German Primary Central Nervous System Lymphoma Study Group
Sep 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kristoph JahnkeEckhard Thiel
Mar 8, 2011·Hematological Oncology·Sawyna ProvencherHervé Ghesquières
Jun 21, 2011·European Journal of Radiology·Gernot Schulte-AltedorneburgHendrik Pels
Sep 15, 2011·British Journal of Cancer·J L VillanoB J McCarthy
Dec 22, 2011·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Yang Yang, Johannes Czernin
Jun 15, 2014·Neurology·Matthias HoldhoffXiaobu Ye
Feb 27, 2015·Neurology·Edward A Neuwelt, David Schiff
Mar 12, 2015·Acta Oncologica·Liisa HarjamaOuti Kuittinen
Jul 8, 2015·The Lancet Oncology·Khê Hoang-XuanUNKNOWN European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma
May 3, 2016·The Lancet. Haematology·Andrés J M FerreriUNKNOWN International Extranodal Lymphoma Study Group (IELSG)
Jun 5, 2017·Fluids and Barriers of the CNS·Prakash AmbadyEdward A Neuwelt
Sep 15, 2018·Best Practice & Research. Clinical Haematology·Maya S Graham, Lisa M DeAngelis
Jan 12, 2019·The Lancet Oncology·Jacoline E C BrombergJeanette K Doorduijn
Feb 7, 2020·Journal of Neuro-oncology·Prakash AmbadyEdward A Neuwelt